| Date | Title | | | 12/06/12 | Medgenics Key Patent Claims Allowed in Japan Protecting Core Technology to be Used in Hepatitis Treatment|
Expands global patent protection for Medgenics’ proprietary
Biopump platform
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Dec. 6, 2012--
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the
“Company”), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using their
own tissue, today announced it has received a Notice of Allowance from
the Japanese Patent and Tra... |
|  | | 11/28/12 | Renowned Experts Affirm Potential of Medgenics’ INFRADURE Technology for the Treatment of Hepatitis B and D| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Nov. 28, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the
“Company”), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using their
own tissue, today announced that during the recent annual conference of
the American Association for the Study of Liver Disease (AASLD) in
Boston, it convened an active roundtable of top l... |
| | | 11/21/12 | Medgenics Granted U.S. Patent for Core Technology Used in Sustained Delivery of Erythropoietin, Aimed at Multi-Billion Dollar Anemia Market|
U.S. Patent and Trademark Office also allowed key claims
protecting similar method for delivery of clotting Factor VIII aimed at
sustained treatment of hemophilia
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Nov. 21, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the
“Company”), the developer of BiopumpTM a novel technology for
the sustained production and delivery of therapeutic proteins in
patients using their ... |
| | | 11/14/12 | Medgenics Reports Third Quarter 2012 Financial Results| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Nov. 14, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the
“Company”), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using their
own tissue, today reported financial results for three and nine months
ended September 30, 2012.
Business Highlights of the Third Quarter and Subsequent Weeks
... |
| | | 11/02/12 | Medgenics Presents Preliminary Data from Phase IIa Study with EPODURE to Treat Anemia in Dialysis Patients at Kidney Week 2012| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Nov. 2, 2012--
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the
developer of Biopump™, a novel technology for the sustained production
and delivery of therapeutic proteins in patients using their own tissue,
announced the presentation of preliminary data from its ongoing Phase
IIa clinical trial in Israel with EPODURE™ Biopumps to treat anemia in
patients on dialysis with end-stage renal d... |
| | | 10/23/12 | Medgenics Announces EPODURE to be Presented in Poster Session at the American Society of Nephrology’s Kidney Week 2012|
Study investigating Stabilization of Hemoglobin Levels in Anemic
Patients with End Stage Renal Disease using EPODURE Biopumps
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Oct. 23, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the
“Company”), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using their
own tissue, today announced the Company will be presen... |
| | | 10/16/12 | Medgenics Announces Filing of Shelf Registration| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Oct. 16, 2012--
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the
“Company”) today announced that it has filed a shelf registration
statement on Form S-3 with the Securities and Exchange Commission
(“SEC”).
Under the shelf registration statement, once declared effective by the
SEC, the Company may offer and sell from time to time in the future, in
one or more offerings, commo... |
| | | 08/29/12 | Medgenics’ Novel Tissue Implant Approved for Two Hepatitis C Clinical Trials in Israel|
First in man clinical trials of INFRADURE Biopumps for the
continuous production of interferon alpha from patient’s own tissue
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Aug. 29, 2012--
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the
developer of Biopump™, a novel technology for the sustained production
and delivery of therapeutic proteins in patients using their own tissue,
today announced that Israel’s Ministry of Health... |
| | | 08/28/12 | Medgenics Mourns the Loss of Board Member Gary Brukardt| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Aug. 28, 2012--
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the
developer of Biopump™, a novel technology for the sustained production
and delivery of therapeutic proteins in patients using their own tissue,
announces the passing of Director Gary Brukardt on Tuesday, August 21,
2012. Mr. Brukardt, age 66, had served on the Company’s Board of
Directors since 2006 and was a member of the Au... |
| | | 08/14/12 | Medgenics Appoints Dr. Marvin Garovoy as Chief Medical Officer|
Brings 16 years of drug development experience with biotechnology
leaders including Genentech
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Aug. 14, 2012--
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the
developer of Biopump™, a novel technology for the sustained production
and delivery of therapeutic proteins in patients using their own tissue,
is pleased to announce the appointment of Marvin Garovoy, M.D. as Chief
Me... |
| | | 08/13/12 | Medgenics Announces Second Quarter 2012 Financial Results| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Aug. 13, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the
“Company”), the developer of Biopump™, a novel technology for the
sustained production and delivery of therapeutic proteins in patients
using their own tissue, today announced financial results for three and
six months ended June 30, 2012, and the filing with the U.S. Securities
and Exchange Commission (“SEC”) of the Company... |
| | | 07/23/12 | Medgenics Announces Registration of Shares to Be Issued upon Exercises of Warrants Listed on NYSE MKT| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jul. 23, 2012--
Medgenics, Inc. (NYSE MKT: MDGN and MDGN.WS and AIM: MEDG and MEDU), the
developer of BiopumpTM, a novel technology for the sustained
production and delivery of therapeutic proteins in patients using their
own tissue, today announced the availability of a current prospectus
following the effectiveness of its registration in the United States of
common stock issuable upon the exercis... |
| | | 07/17/12 | First Subjects Enrolled in Phase IIa Clinical Trial of EPODURE Biopumps to Treat Anemia in Patients with End-Stage Renal Disease on Dialysis| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jul. 17, 2012--
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the
developer of Biopump™, a novel technology for the sustained production
and delivery of therapeutic proteins in patients using their own tissue,
announces the launch of its Phase IIa clinical trial in Israel of
EPODURE™ Biopumps to treat anemia in patients with end-stage renal
disease (“ESRD” or “kidney failure”) on dialysis, ... |
| | | 07/02/12 | Medgenics Appoints Former Celgene CEO Dr. Sol Barer as Chairman of the Board|
Barer led biotechnology company Celgene to $25 billion market
capitalization
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jul. 2, 2012--
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the
developer of BiopumpTM, a novel technology for the sustained
production and delivery of therapeutic proteins in patients using their
own tissue, today announced that former Celgene Corporation Chairman and
Chief Executive Officer, Sol J... |
| | | 06/20/12 | Medgenics Receives Orphan Drug Designation from FDA for INFRADURE Biopump to Treat Hepatitis D|
May accelerate regulatory pathway for portfolio of Biopump
indications
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jun. 20, 2012--
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the
developer of BiopumpTM, a novel technology for the sustained
production and delivery of therapeutic proteins in patients using their
own tissue, today announced that its INFRADURE™ Biopump has received
Orphan Drug Designation from the U.S. F... |
| | | 06/19/12 | Medgenics, Inc. Raises $9.5 Million in Private Placement| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jun. 19, 2012--
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of a
novel Biopump™ technology for the sustained production and delivery of
therapeutic proteins in patients using their own tissue, today announced
it has raised gross proceeds of approximately $9.5 million
(approximately $8.4 million net) through the sale of 1,944,734 units
(the “Units”), with each Unit consisting... |
| | | 06/07/12 | Medgenics Initiates U.S. Biopump Processing Site|
Facility initially to supply EPODURE for U.S. anemia clinical
trials
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jun. 7, 2012--
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of
the novel Biopump™ technology for the sustained production and delivery
of therapeutic proteins in patients using their own tissue, announced
today it has initiated its first U.S. Biopump processing facility in
Davis, California.
... |
| | | 05/18/12 | Medgenics to Present at the 11th Annual ILSI BIOMED 2012| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--May. 18, 2012--
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the
“Company”), the developer of the novel Biopump™ technology for the
sustained production and delivery of therapeutic proteins in patients
using their own tissue, today announced that Andrew L. Pearlman, Ph.D.,
the Company’s President and CEO, will present a corporate overview at
the 11th Annual Israeli Life Sciences Industry B... |
| | | 05/17/12 | Medgenics Receives FDA Clearance to Commence Phase IIb Trial of EPODURE for Sustained Anemia Treatment in Dialysis Patients|
First U.S. Study with Company’s Biopump Platform Marks Major
Milestone
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--May. 17, 2012--
Medgenics, Inc. (NYSE MKT: MDGN)(AIM: MEDU)(AIM: MEDG) (the “Company”),
developer of the novel Biopump™ technology for the sustained production
and delivery of therapeutic proteins in patients using their own tissue,
today announced receipt of clearance from the U.S. Food and Drug
Administration (“... |
| | | 05/14/12 | Medgenics Announces First Quarter 2012 Financial Results| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--May. 14, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the
“Company”), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using their
own tissue, today announced financial results for three month ended
March 31, 2012, and the filing with the U.S. Securities and Exchange
Commission (“SEC”) of the Company’s Quarterly Repor... |
| | | 05/09/12 | Medgenics Awarded $2.2 Million Grant from the Israeli Office of the Chief Scientist| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--May. 9, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the
developer of a novel technology for the sustained production and
delivery of therapeutic proteins in patients using their own tissue,
today reported that its wholly owned subsidiary, Medgenics Medical
Israel Ltd. (MMI) was awarded a government grant of up to NIS 8.1
million (approximately USD 2.2 million), net, from the Offic... |
| | | 04/26/12 | Medgenics Comments on Market Trading Activity| MISGAV, Israel and SAN FRANCISCO, Apr 26, 2012 (BUSINESS WIRE) --Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the
developer of a novel technology for the sustained production and
delivery of therapeutic proteins in patients using their own tissue,
today announces that the NYSE Amex contacted the Company and, in
accordance with its usual practice, requested that the Company issue a
press release regarding the increased activity in the trading of i... |
| | | 04/23/12 | Medgenics Files for U.S. Orphan Drug Designation for INFRADURE for
the Treatment of Hepatitis D| Designation could open pathway to expedited approval of platform
protein delivery technology and additional market exclusivity
MISGAV, Israel & SAN FRANCISCO, Apr 23, 2012 (BUSINESS WIRE) --Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the
developer of a novel technology for the sustained production and
delivery of therapeutic proteins in patients using their own tissue,
today announced that it has filed for Orphan Drug Designation with the... |
| | | 04/17/12 | Medgenics Files IND Application for EPODURE Biopump Phase IIb Anemia
Study in Dialysis Patients| First FDA Filing for Biopump in the U.S. Expected to Build Upon
Positive Results from Pre-Dialysis Study
MISGAV, Israel & SAN FRANCISCO, Apr 17, 2012 (BUSINESS WIRE) --Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the
developer of a novel technology for the sustained production and
delivery of therapeutic proteins in patients using their own tissue,
today announced that it has filed an Investigational New Drug ("IND")
application wi... |
| | | 04/05/12 | Medgenics Announces Results of 2012 Annual Meeting of Stockholders| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Apr. 5, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the
“Company”), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using their
own tissue, today announces that all resolutions proposed at the
Company’s Annual Meeting of Stockholders held yesterday were duly passed.
Each of the current directors of the Compa... |
| | | 03/26/12 | Medgenics Reports Positive Meeting With NIH Recombinant DNA Advisory Committee|
Clears Important Hurdle Toward U.S. Phase II Clinical Trial of
EPODURE for Sustained Treatment of Anemia in Kidney Disease Patients on
Dialysis
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Mar. 26, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the
developer of a novel technology for the sustained production and
delivery of therapeutic proteins in patients using their own tissue,
today announced that it has recei... |
| | | 03/23/12 | Medgenics Cleared to Initiate Phase IIa Anemia Study of EPODURE Biopump in Dialysis Patients in Israel|
Study of New Indication in Dialysis Expected to Build on Positive
Results from Pre-Dialysis Study
MISGAV, Israel and SAN FRANCISCO--(BUSINESS WIRE)--Mar. 23, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the
developer of a novel technology for the sustained production and
delivery of therapeutic proteins in patients using their own tissue,
today announced receipt of clearance from the Israeli Ministry of Health
to initi... |
| | | 03/21/12 | Medgenics to Present at the Maxim Group Growth Conference| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Mar. 21, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the
developer of a novel technology for the sustained production and
delivery of therapeutic proteins in patients using their own tissue,
today announced that Andrew L. Pearlman, Ph.D., President and Chief
Executive Officer of Medgenics, will present a corporate overview and
update at the Maxim Group Growth Conference being held... |
| | | 03/13/12 | Medgenics Announces Participation in Roth Conference and Other Matters| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Mar. 13, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the
developer of a novel technology for the sustained production and
delivery of therapeutic proteins in patients using their own tissue,
today announced that Andrew L. Pearlman, Ph.D., President and Chief
Executive Officer of the Company, will deliver a corporate overview at
the 24th Annual Roth Conference taking place March 11... |
| | | 03/06/12 | Medgenics Announces 2011 Financial Results| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Mar. 6, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the
“Company”), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using their
own tissue, today announced financial results for the year ended
December 31, 2011, and the filing with the U.S. Securities and Exchange
Commission (“SEC”) of the Company’s Annual Report on... |
| | | 02/15/12 | Medgenics To Present At LHA Life Sciences & Medical Technologies Virtual Conference| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Feb. 15, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the
“Company”), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using their
own tissue, today announced that Andrew L. Pearlman, Ph.D., President
and Chief Executive Officer of Medgenics, will present to investors as
part of the LHA Life Sciences & Medical Tec... |
| | | 01/25/12 | Medgenics Sets Record Date for 2012 Annual Meeting of Stockholders| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jan. 25, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the
“Company”), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using their
own tissue, today announced that its Board of Directors has set the
close of business on March 2, 2012 (5:00 p.m., PST) as the record date
for stockholders entitled to vote at the Company’... |
| | | 01/24/12 | Medgenics Adds Two Key Opinion Leaders to Strategic Advisory Board|
Renowned Liver and Kidney Disease Experts Significantly Enhance
Advisory in Two Leading Indications for Company’s Protein Production
Technology
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jan. 24, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the
“Company”), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using their
own tissue, today announced t... |
| | | 01/20/12 | Medgenics' Receives Allowance for Key European Patent|
Follows Similar U.S. Patent for Biopump Protein Therapy Technology
and Expands Intellectual Property Portfolio
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jan. 20, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the developer of
a novel technology for the sustained production and delivery of
therapeutic proteins in patients using their own tissue, today announced
that the Company received notice of ‘Intention to Grant’ ... |
| | | 01/09/12 | Medgenics, Inc. Announces Issue of Options and Restricted Shares to Directors and Officers| MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jan. 9, 2012--
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the developer of
a novel technology for the sustained production and delivery of
therapeutic proteins in patients using their own tissue, announces that,
pursuant to approvals given at a Board meeting held on 9 December 2011,
on 3 January 2012 it (i) granted options to subscribe for 15,000 common
shares (“Options”) and (ii) made ... |
| |
|
Print Page | 
E-mail Page | 
RSS | 
E-mail Alerts | 
Contact IR
